# Spinoff company BioVersys announces investment in clinical development of its lead asset BV100 in China

**Source**: https://bsse.ethz.ch/news-and-events/d-bsse-news/2024/09/spinoff-company-bioversys-announces-investment-in-clinical-development-of-its-lead-asset-bv100-in-china.html
**Parent**: https://bsse.ethz.ch/news-and-events/d-bsse-news.html?AUTHOR=Q2Fyb2xpbiBBcm5kdCBGb3BwYQ&path=L2NvbnRlbnQvc3BlY2lhbGludGVyZXN0L2Jzc2UvZGVwYXJ0bWVudC9lbi9uZXdzLWFuZC1ldmVudHMvamNyOmNvbnRlbnQvcGFyL25ld3NmZWVkXzQzMTg

On 11 September, D-BSSE spinoff BioVersys announces the investment of US$6m by investment firm Guangzhou-Israel Biotechnology Fund. This investment aligns with BioVersys’ strategic decision to expand its BV100 clinical programme in China. BV100 is a novel formulation of rifabutin suitable for intravenous administration which is targeting specific *Acinetobacter baumannii* - bacteria, an opportunistic pathogen in humans, typically infecting critically ill and immunocompromised patients.

Find [external page media release issued by biopharmaceutical company BioVersys](https://www.bioversys.com/5454-2/) on 11 September 2024.

Learn about [D-BSSE spinoff companies](/department/spin-offs.html).\